Mode
Text Size
Log in / Sign up
N/A N=12 Treatment

Atrial Deganglionation as a Therapy for Cardiac Surgery Patients With Atrial Fibrillation

Atrial Fibrillation

Enrolled (actual)
12
Serious AEs
8.3%
Results posted
Jul 2024
Primary outcome: Primary: The Number of Patients in Sinus Rhythm at 12 Months. — 12 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Pulsed Field Ablation of epicardial Ganglionated Plexi. (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Atrian Medical Ltd.
Primary completion
Jun 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
The Number of Patients in Sinus Rhythm at 12 Months.
12
SECONDARY
Extension of AERP
12

Summary

A prospective single-arm study of ganglionated plexi ablation in cardiothoracic surgery patients with a history of atrial fibrillation.

Eligibility Criteria

Inclusion Criteria

  • Age is between 18 and 70 years.
  • Scheduled for open-chest cardiothoracic surgery, for coronary artery bypass grafting and/or aortic valve repair/replacement
  • Have a documented medical history of paroxysmal or early-stage persistent atrial fibrillation within the previous 12 months.
  • Legally competent and willing to sign the informed consent.
  • Life expectancy of at least 2 years.

Exclusion Criteria

  • Previous cardiac surgery
  • Prior pericardial interventions
  • Prior endocardial or epicardial pulmonary vein isolation (PVI), or any other invasive AF therapy
  • Previous or existing pericarditis
  • Use of amiodarone within the previous 12 months.
  • Long-standing persistent atrial fibrillation
  • Indication for mitral or tricuspid valve surgery
  • Indication for concomitant left atrial appendage (LAA) ligation or excision
  • History of previous radiation therapy on the thorax
  • History of previous thoracotomy.
  • Prior electrical or mechanical isolation of the Left Atrial Appendage (LAA)
  • The presence of LAA occlusion devices, coronary stents, prosthetic heart valves, pacemakers or implantable cardioverter defibrillators (ICDs)
  • Myocardial infarction within the previous 2 months
  • New York Heart Association (NYHA) Class IV heart failure symptoms
  • Left Ventricular Ejection Fraction (LVEF) 5.0 cm, measured by transthoracic echocardiography (TTE)
  • The presence of left atrial thrombus when examined by transesophageal echocardiography (TEE)
  • The presence of atrial fibrillation (AF) attributable to non-cardiovascular causes such as thyroid disease, electrolyte imbalance/dehydration or other reversible causes
  • Active infection or sepsis as evidenced by increased white blood cell count, elevated C-reactive protein (CRP) or temperature > 38.5°C
  • Known or documented carotid stenosis > 80%
  • Stroke or transient ischemic attack within the previous 6 months
  • Known or documented epilepsy
  • Pregnancy or child-bearing potential without adequate contraception
  • Circumstances that prevent follow-ups
  • Drug abuse
  • Patients cannot be enrolled in another clinical study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05426759). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search